Introduction
============

The last decade has seen the mouse become one of the model species of choice for researchers studying brain function and neuropsychiatric diseases. This trend has been catalyzed by two key scientific advances during this period: the emergence of techniques for precisely manipulating the mouse genome, such as gene-targeting (Capecchi, [@B26]), and the sequencing of the human genome (International Human Genome Sequencing Consortium, [@B68]). In addition, the mouse lends itself to the application of other techniques, both traditional (e.g., drug treatments, brain lesions) and cutting-edge (e.g., RNA interference, opticogenetics), for manipulating molecules, neurotransmitters and circuits in the brain. As such, the mouse-based laboratory is now equipped with a potent armamentarium of techniques to tackle the study of neuropsychiatric disorders. By joining forces with increasingly powerful techniques for studying human subjects, such as genome-wide association studies and brain imaging (Harrison and Weinberger, [@B61]; Robbins, [@B98]; Hariri and Holmes, [@B60]), the hope is that research using mice can allow us to make some truly novel insights into the pathophysiology and treatment of neuropsychiatric diseases, including schizophrenia.

Arguably, the development of sophisticated, translatable mouse-based assays for the behavioral manifestations of schizophrenia has lagged the advances in molecular and genomic techniques. Contrary to a commonly voiced opinion, we do not believe that this is because mice are "not smart enough" to perform complex behavioral, particularly cognitive, assays, but rather that an adequate investment of time and effort has not been put into adapting and validating procedures for the mouse.

In a collaborative venture with Bussey, Saksida and colleagues, our laboratory has made efforts to fill this gap by investing in the development of novel assays, including adapting a touchscreen-based method for measuring cognitive and [executive functions](#G1){ref-type="other"} for use in mice (Izquierdo et al., [@B69]), and by validating existing models of schizophrenia, such as subchronic phencyclidine (PCP) treatment, in the touchscreen system and other mouse assays. We have sought to utilize these assays to elucidate mechanisms subserving complex behaviors and disease-related behavioral dysfunctions. As part of these efforts, we have examined pharmacological models of schizophrenia in our tasks, and recently reported on the effects of subchronic PCP treatment on social behavior and cognition (touchscreen-based visual discrimination and [reversal learning](#G2){ref-type="other"}) in non-mutant mice (Brigman et al., [@B17]). Here, we summarize these results and put them in the larger context of ongoing efforts in the field to develop valid models of schizophrenia, or at least assays for some of the main symptoms of the disease, in mice. We begin with a brief overview of how the major symptoms of schizophrenia are clinically categorized and assayed by mouse behavioral tests. We go on to discuss in greater detail various mouse assays for "[cognitive flexibility](#G3){ref-type="other"}", including reversal learning -- a type of executive function impaired in schizophrenia that we and others have highlighted as a particularly tractable, translatable process to measure in rodent models of schizophrenia. We end with some concluding remarks on some key questions to be addressed in future work.

Modeling Major Symptom Categories of Schizophrenia in Mice
==========================================================

Schizophrenia is a highly heterogeneous disorder of myriad symptoms. The presentation of different symptoms and their severity varies considerably across patients. While this complexity cannot be fully recapitulated in the mouse, specific symptom categories can be behaviorally modeled in mice. A constructive starting point has been to demarcate schizophrenia-related phenotypes into the clinical categories of positive, negative and cognitive/executive symptoms (Arguello and Gogos, [@B5]; Powell and Miyakawa, [@B95]).

Positive symptoms are so-called because they add to the normal behavioral repertoire. While a mouse test for hallucinations has not yet been proffered, other positive symptoms, such as psychomotor agitation and hyper-responsivity to psychotomimetic drugs, can be modeled in mice by testing locomotor responses (particularly under provocative situations, such as stressful environments) (Figure [1](#F1){ref-type="fig"}A), and locomotor hyperactivity-inducing effects of psychostimulants (e.g., amphetamine) and other psychotomimetics \[e.g., *N*-methyl-[δ]{.smallcaps}-aspartate receptor (NMDAR) antagonists dizocilpine/MK-801 or PCP; Figure [1](#F1){ref-type="fig"}B\].

![**Mouse behavioral assays for the major symptom categories of schizophrenia**. *Positive symptoms*. The psychomotor agitation and hyper-responsivity to psychotomimetic drugs found in schizophrenia can be modeled in mice by testing locomotor responses in novel and stressful environments **(A)** and locomotor hyperactivity-inducing effects of psychotomimetics, such as NMDAR antagonists **(B)**, respectively. *Negative symptoms*. Schizophrenia is often associated with blunted affect, social withdrawal, and loss of pleasure in normally rewarding activities (anhedonia). Social interactions with other mice **(C)** and decreased preference or motivation to obtain rewarding substances, such as sucrose **(D)**, can be assessed as a means to model these negative symptoms. *Cognitive/executive symptoms*. Abnormalities in cognition and executive functions are a prominent feature of schizophrenia and range from deficits in episodic memory, poor attention and sensorimotor gating, to impaired reversal learning and set-shifting. Learning and memory can be tested in mice using, e.g., the reference memory version of the Morris water maze **(E)**, while prepulse inhibition of the startle response provides a ready measure of sensorimotor gating **(F)**.](fnins-04-013-g001){#F1}

Rodent models of schizophrenia have traditionally focused on positive symptoms, and this has provided many important mechanistic insights and drug leads. However, there has been a growing emphasis on studying, modeling and treating the negative and cognitive/executive symptoms of the disease (Carter et al., [@B27]). Negative symptoms (so-called because they subtract from the normal behavioral repertoire) include blunted affect, social withdrawal and loss of pleasure in normally rewarding activities (anhedonia). Various rodent assays for social behavior and anhedonia (e.g., decreased preference or motivation to obtain rewarding substances such as sucrose) have been typically used to model other disorders, such as anxiety (File and Seth, [@B48]), autism (Crawley, [@B36]) and depression (Strekalova et al., [@B111]), but also lend themselves well to the study of abnormalities in these behaviors in models of schizophrenia (Figures [1](#F1){ref-type="fig"}C,D).

The category of cognitive/executive symptoms covers a range of abnormalities: from deficits in episodic memory to impaired attention and sensorimotor gating. Assays for prepulse inhibition and latent inhibition provide ready measures of sensorimotor gating and selective attention, respectively, that can be applied across species (Figure [1](#F1){ref-type="fig"}F). Both have been widely employed as a screen for antipsychotics and a measure of schizophrenia-related phenotypes in mutant mice (Feldon and Weiner, [@B45]; Geyer et al., [@B55]). There are also numerous very well-studied methods for testing various forms of cognition, such as the spatial reference memory version of the Morris water maze (Figure [1](#F1){ref-type="fig"}E). However, although impaired episodic memory is one of the strongest features of the cognitive profile of schizophrenia (Ranganath et al., [@B97]), rodent models of this disease have not relied upon such measures -- perhaps because they do not distinguish a model of schizophrenia from other conditions that are also characterized by memory deficits, e.g., Alzheimer\'s disease.

Mouse Assays for Cognitive Flexibility
======================================

Executive functions subserve the selection and processing of information necessary to plan, control and direct behavior in a manner appropriate to current environmental demands. Across species, these processes are mediated by neural circuitry including the prefrontal cortex (PFC) and interconnected subcortical regions, such as the striatum (Goldman-Rakic, [@B57]; Miller and Cohen, [@B90]; Floresco et al., [@B51]). Pathology in these circuits is a hallmark of schizophrenia (Robbins, [@B98]; Lewis and Gonzalez-Burgos, [@B87]; Tan et al., [@B113]), and is specifically tied to the profound executive deficits exhibited by schizophrenic patients on measures of cognitive flexibility described below.

Cognitive flexibility is a critical executive function that can be broadly defined as the ability to adapt behaviors in response to changes in the environment. The Wisconsin Card Sorting Task (WCST; Grant and Berg, [@B59]) has been one of the more commonly employed assays for impaired cognitive flexibility in schizophrenic patients, and analogous versions have been developed for use in lower species, including mice (Table [2](#T2){ref-type="table"}). In essence, these tasks involve the subject selecting between stimuli, which vary from one another in more than one perceptual dimension (or "set"), and being reinforced for choosing a stimulus based upon one specific dimension alone, e.g., odor. During an "intra-dimensional shift" (IDS), the form of the dimension the subject must choose is changed by the experimenter, e.g., from cinnamon to chocolate odor. In an "extra-dimensional shift" (EDS), the correct dimension is changed altogether, such that choices must be guided by the new dimension (texture) while ignoring the previously rewarded dimension.

In a rodent IDS/EDS analog of the WCST, rats (Birrell and Brown, [@B10]) or mice (Colacicco et al., [@B32]; Garner et al., [@B52]; Bissonette et al., [@B11]) dig in sand to make choices based on the dimension of texture or smell (Figure [2](#F2){ref-type="fig"}A). As in humans, this task is sensitive to PFC damage in rats (Birrell and Brown, [@B10]) and mice (Bissonette et al., [@B11]). One potentially salient difference with the human procedure is that the dimensions are in different sensory modalities \[note: attempts to date to develop a IDS/EDS task using a single (visual) modality have not demonstrated the formation of an attentional set in the mouse (Brigman et al., [@B15])\].

![**Mouse behavioral assays for cognitive flexibility**. **(A)** *Intra-dimensional/extra-dimensional digging task*. Mice are trained to dig for food reward using either olfactory (digging medium odor) or tactile (digging medium texture) cues. The rewarded cue in the same dimension is switched to test for intra-dimensional shifting. The rewarded cue is changed to the different dimension to test for extra-dimensional shifting. **(B)** *Spatial reversal in Morris water maze*. After learning to locate a submerged platform using distal spatial cues (see Figure [1](#F1){ref-type="fig"}E), the platform location is moved to the opposite side of the pool to test for reversal. **(C)** *Spatial reversal in T-maze*. After learning to locate a food reward in one goal arm using distal spatial cues, the rewarded goal arm is switched to test for reversal. **(D)** *Reversal of discriminated operant response in a bar-pressing system*. After learning to press a lever for reward based on a visual (e.g., light) or spatial (lever location) cue, the rewarded cue is switched to test for reversal. **(E)** *Reversal of discriminated operant response in a touchscreen-based system*. Reversal of a discriminated operant response can also be tested using a touchscreen-based system (for details, see Figure [3](#F3){ref-type="fig"}).](fnins-04-013-g002){#F2}

Reversal learning provides another measure of cognitive flexibility. Subjects first learn a stimulus-reward association, then the reward association is switched. Although reversal learning has been described as hierarchically less complex than set-shifting, it requires flexible switching between cues within the same perceptual dimension or modality, and taxes multiple executive functions, including attention, working memory and response inhibition (Roberts, [@B100]). In addition, reversal learning paradigms allow for a direct measure of perseverative responding to a previously rewarded stimuli or cue, as it is present, but unrewarded, during the reversal phase. This is particularly pertinent because perseveration, possibly caused by insensitivity to negative feedback (i.e., non-reward) following incorrect responding, is a feature of impaired reversal in schizophrenia (Leeson et al., [@B86]).

Touchscreen-Based Measure of Reversal Learning in Mice
======================================================

Various tasks have been developed to measure reversal in rats and mice in maze (Mackintosh et al., [@B88]; Ragozzino et al., [@B96]; Stefani et al., [@B110]; Floresco et al., [@B50]) as well as operant settings (e.g., Ferry et al., [@B46]; Schoenbaum et al., [@B105]; Bohn et al., [@B12],[@B13]; Schoenbaum et al., [@B106]) (Figures [2](#F2){ref-type="fig"}B--D). In an effort to provide a procedure that was more analogous and comparable to reversal tasks being employed in patients (Robbins et al., [@B99]) and higher species (non-human primates), Bussey and colleagues established a [touchscreen-based operant system](#G4){ref-type="other"} in which rats and mice learn to discriminate and reverse between two visual stimuli projected onto a touch-sensitive computer screen (Bussey et al., [@B23], [@B25]) (Figure [2](#F2){ref-type="fig"}E). Demonstrating the translatable potential for mapping mouse studies onto systems in the human, reversal performance in this system is PFC-dependent, as confirmed by lesion studies in the rat (Bussey et al., [@B22]; Chudasama and Robbins, [@B30]) and to some extent in the mouse (Brigman and Rothblat, [@B19]).

In addition to its comparability to human measures of reversal, this paradigm has several unique benefits (for discussion, see Bussey et al., [@B24]). Of note, the automation of the task makes it relatively free of experimenter influences that can vary across individuals and laboratories, and influence results (Crabbe et al., [@B35]). The system is also very flexible and can be easily adapted to test for other forms of cognition and executive function other than discrimination and reversal, such as extinction (Hefner et al., [@B62]), spatial paired-associate learning (associating an object with a spatial location) (Talpos et al., [@B112]) and pattern separation (discrimination of perceptually similar stimuli) (Clelland et al., [@B31]).

In our formulation of the task (Izquierdo et al., [@B69]; Brigman et al., [@B16]) (Figure [3](#F3){ref-type="fig"}), mice are first trained to initiate the appearance of the stimuli on-screen by a head entry into a magazine where food pellets are delivered (Figure [3](#F3){ref-type="fig"}A). There is then some training to shape the mouse to touch the screen to obtain reward before discrimination learning begins (Figure [3](#F3){ref-type="fig"}B). Discrimination is typically between two (i.e., pairwise) distinct visual stimuli, with responses on one stimulus rewarded with food and responses on the other producing a timeout period during which additional responses cannot be made (Figure [3](#F3){ref-type="fig"}C). After reaching a pre-determined criterion of discrimination (e.g., \>85% correct choices), the stimulus-reward contingencies are reversed and the subject must inhibit perseverative responses to the previously rewarded stimulus and learn to respond to the alternate, previously unrewarded, stimulus (Figure [3](#F3){ref-type="fig"}D).

![**Touchscreen-based operant system for assaying discrimination and reversal learning in mice**. Training and testing entails four stages. **(A)** To first teach the mouse to associate rewards with visual stimuli on the touchscreen, food pellets and stimuli are presented concomitantly. **(B)** Next, the mouse must respond to stimuli on the screen to obtain a reward (and also initiate new trials via a head-entry into the magazine). **(C)** During discrimination learning, two novel stimuli are presented on the screen, and the mouse must respond to one stimulus (to obtain reward) and not the other (to avoid non-reward and a timeout phase during which no new trials can be initiated). **(D)** In the final stage, the stimulus-reward contingency is reversed, and the mouse must now respond to the previously unrewarded stimulus to obtain reward. Note: the left/right position of rewarded stimuli varies pseudorandomly across trials, and the type of rewarded stimulus is counterbalanced across mice.](fnins-04-013-g003){#F3}

The capacity for this system to concurrently assess discrimination as well as reversal learning provides an excellent internal control, not only for learning and behavioral performance generally, but also because discrimination is impaired in some cases of schizophrenia. For example, discrimination and reversal learning were significantly impaired in chronic hospitalized schizophrenic patients with frontal lobe damage (Pantelis et al., [@B93]). Interestingly, more stabilized patients were found to be more specifically impaired on reversal and EDS shifts (Elliott et al., [@B44]; Waltz and Gold, [@B117]) and some first-episode schizophrenics exhibited even more restricted, EDS-only, impairment (Hutton et al., [@B66]; Joyce et al., [@B76]; Braw et al., [@B14]). These findings raise the interesting possibility that the profile of discrimination/reversal/set-shifting impairment may be graded in a manner corresponding to the chronicity of schizophrenia (Joyce et al., [@B76]). On the other hand, there are clinical data showing clear deficits in both reversal and set-shifting in first-episode schizophrenics, and especially in those patients with prominent thought disorganization symptoms (Barnett et al., [@B9]; Murray et al., [@B91]; Leeson et al., [@B86]). One interpretation of these findings is that the breadth and pattern of deficits in discrimination/reversal/set-shifting may be more of a marker for specific subtypes of the disease rather than of disease severity (Leeson et al., [@B86]). The touchscreen procedure could prove to be valuable for delineating discrimination and reversal impairments in mouse models, and thereby shed light on the pathophysiology underlying their dissociation in different subpopulations of schizophrenic patients.

Effects of Subchronic PCP Treatment on Discrimination and Reversal
==================================================================

There is compelling evidence implicating the glutamate system in the pathophysiology of schizophrenia (Coyle, [@B34]). As part of a larger research program to elucidate the role of glutamate in cognitive and executive functions, we have studied the effects of null mutations in various components of the glutamate system on the touchscreen-based method (Brigman et al., [@B16]; Karlsson et al., [@B77]; Wiedholz et al., [@B118]; Karlsson et al., [@B78]). To compliment and extend these studies, we (Brigman et al., [@B17]) investigated a pharmacological model of glutamatergic dysfunction in schizophrenia -- [subchronic PCP](#G5){ref-type="other"} treatment.

PCP and other NMDAR antagonists (e.g., ketamine) mimic positive and negative symptoms of schizophrenia in otherwise healthy individuals (Javitt and Zukin, [@B70]; Krystal et al., [@B83]). Based upon this observation, Jentsch and colleagues subchronically treated monkeys and rats with PCP and found cognitive deficits and associated prefrontal neurochemical abnormalities (reviewed in Jentsch and Roth, [@B73]). The subchronic PCP model has since been quite widely employed as a rodent model for executive dysfunctions in schizophrenia.

In order to test the subchronic PCP model in the touchscreen-based assay, Brigman et al. ([@B17]) treated C57BL/6J mice with 5 mg/kg PCP twice daily for 7 days and, after a 7-day withdrawal period, tested for discrimination and (in a separate group of mice) reversal in the touchscreen-based task. This treatment and withdrawal duration was based on previous work by Jentsch et al. ([@B71]). Results showed no significant impairments in drug-treated mice in comparison to vehicle treated controls on either discrimination or reversal, as measured using a range of dependent variables. By contrast, the same treatment regimen that failed to affect discrimination or reversal was sufficient to reduce social behavior -- demonstrating that treatment was sufficient to mimic some symptoms of schizophrenia.

While Brigman et al. ([@B17]) was the first study of the PCP model in a rodent touchscreen-based procedure, the lack of impairment may appear somewhat surprising, given PCP-induced deficits have been found on other measures of reversal in rats and mice (summarized in Table [1](#T1){ref-type="table"}). However, similar to Brigman et al., negative effects on reversal have also been reported (including in studies in which there are clear PCP-induced deficits in the EDS component, e.g., Rodefer et al., [@B101], [@B102]; Egerton et al., [@B40]). Direct comparisons between studies are further complicated by variations in treatment regimen and methodology. For example, while Neill and colleagues (Abdul-Monim et al., [@B3], [@B1]) have demonstrated reversal impairments in a light-cue based operant task in rats subjected to a PCP treatment and withdrawal procedure comparable to Brigman et al., their task required subjects to completely inhibit responses on some trials to obtain reward, which likely placed greater demands on inhibitory control than the task used by Brigman et al. (in which a response was always available). This is likely a salient difference because subchronic PCP treatment impairs inhibitory control in rats and non-human primates (Jentsch et al., [@B72], [@B74]; Jentsch and Taylor, [@B75]). Clearly, further work is needed to parse the most critical features of reversal assays that render them sensitive to subchronic PCP treatment.

###### 

**Studies on the effects of acute and chronic PCP treatment on measures of cognitive flexibility**.

  Species   Assay (stimulus modality)     PCP treatment regimen (dose)                              Reference
  --------- ----------------------------- --------------------------------------------------------- -------------------------------
  Rat       Operant reversal (visual)     Acute (1.0--1.5 mg/kg)                                    Abdul-Monim et al. ([@B2])
  Rat       Operant reversal (visual)     Acute (1.5--2.0 mg/kg)                                    Idris et al. ([@B67])
  Rat       Operant reversal (visual)     Chronic, daily (2 mg/kg) × 7 days, +7 days w/d            Abdul-Monim et al. ([@B3])
  Rat       Operant reversal (visual)     Chronic, daily (2 mg/kg) × 7 days, +7 days w/d            Abdul-Monim et al. ([@B1])
  Mouse     Operant reversal (visual)     Chronic, twice daily (5 mg/kg) × 7 days, +7 days w/d      Brigman et al. ([@B17])
  Rat       Spatial reversal (visual)     Chronic, twice daily (5 mg/kg) × 7 days, +7 days w/d      Jentsch and Taylor ([@B75])
  Rat       IDS/EDS (tactile/olfactory)   Acute (2.58 mg/kg)                                        Egerton et al. ([@B41])
  Rat       IDS/EDS (tactile/olfactory)   Repeated (10--20 mg/kg) on postnatal days P7, 9, 11       Broberg et al. ([@B20])
  Rat       IDS/EDS (tactile/olfactory)   Chronic, daily (2.6 mg/kg) × 5 days, +3 days w/d          Egerton et al. ([@B40])
  Mouse     IDS/EDS (tactile/olfactory)   Chronic, daily (0.63--1.3 mg/kg) × 10 days                Laurent and Podhorna ([@B85])
  Rat       IDS/EDS (tactile/olfactory)   Chronic, twice daily (5 mg/kg) × 7 days, +10 days w/d     Rodefer et al. ([@B101])
  Rat       IDS/EDS (tactile/olfactory)   Chronic, twice daily (5 mg/kg) × 7 days, +10 days w/d     Rodefer et al. ([@B102])
  Monkey    Detour reaching task          Chronic, twice daily (0.3 mg/kg) × 14 days, +7 days w/d   Jentsch et al. ([@B71])

*IDS/EDS, intra-dimensional/extra-dimensional set shifting; w/d, withdrawal period prior to testing*.

###### 

**Examples of studies of cognitive flexibility in mutant mice**.

  Assay       Mutant                                                      Reversal effect          Reference
  ----------- ----------------------------------------------------------- ------------------------ --------------------------------
  IDS/EDS     Hdh^CAC(150)^ knock-in                                      Impaired                 Brooks et al. ([@B21])
  IDS/EDS     Dopamine D2 receptor knockout                               Impaired                 De Steno and Schmauss ([@B39])
  IDS/EDS     Dopamine D3 receptor knockout                               Facilitated              Glickstein et al. ([@B56])
  IDS/EDS     COMT-Val transgenic                                         None                     Papaleo et al. ([@B94])
  IDS/EDS     Tg2576 APP Swedish mutation                                 Impaired                 Zhuo et al. ([@B120])
  MWM         p25 fragment accumulation                                   Facilitated              Angelo et al. ([@B4])
  MWM         Vesicular glutamate transporter deficient                   Impaired                 Balschun et al. ([@B7])
  MWM         *N*-terminal amidase deficient                              Facilitated              Balogh et al. ([@B6])
  MWM         Ins2^C96Y^ Akita                                            None                     Choeiri et al. ([@B29])
  MWM         Rac3 knockout                                               Impaired                 Corbetta et al. ([@B33])
  MWM         TgCRND8 APP double mutant                                   Impaired                 Chishti et al. ([@B28])
  MWM         Synaptic vesicle protein (Rab3a) deficient                  Impaired                 D\'Adamo et al. ([@B37])
  MWM         NaS~i~-1 sulfate transporter deficient                      None                     Dawson et al. ([@B38])
  MWM         PDE1B^−/−^ DARPP32^−/−^ double knockout                     Impaired                 Ehrman et al. ([@B42])
  MWM         CREBcomp mutant                                             Impaired                 Gass et al. ([@B53])
  MWM         mGluR4 deficient                                            Facilitated              Gerlai et al. ([@B54])
  MWM         α3-GABA~a~ deficient                                        Trend for impaired       Fiorelli et al. ([@B49])
  MWM         PS1 transgenic, L235P mutation                              None                     Huang et al. ([@B65])
  MWM         β-amyloid precursor protein transgenic                      Impaired                 Koistinaho et al. ([@B80])
  MWM         D-amino acid oxidase deficient                              Facilitated              Labrie et al. ([@B84])
  MWM         Presenilin 1 knockout                                       Rescues APP transgenic   Saura et al. ([@B103])
  MWM         Protein tyrosine phosphatase-alpha deficient                None                     Skelton et al. ([@B108])
  MWM         Offspring of vasoactive intestinal peptide deficient dams   Impaired                 Stack et al. ([@B109])
  MWM         Guanine nucleotide exchange factor (Ric-8) deficient        Impaired                 Tonissoo et al. ([@B114])
  MWM         CB1 endocannabinoid receptor deficient                      Impaired                 Varvel and Lichtman ([@B115])
  MWM         GDNF receptor α2 deficient                                  Impaired                 Voikar et al. ([@B116])
  Operant     Heterozygous Reln deficient "Reeler Mouse"                  Impaired                 Brigman et al. ([@B18])
  Operant     Heterozygous Reln deficient "Reeler Mouse"                  None                     Krueger et al. ([@B81])
  Olfactory   TgS and TgR acetylcholinesterase disruption                 None                     Kofman et al. ([@B79])
  Olfactory   Dopamine D2 receptor knockout                               Impaired                 Kruzich et al. ([@B82])
  Olfactory   Phenylalanine hydroxylase deficient                         Impaired                 Zagreda et al. ([@B119])
  Spatial     AMPA receptor subunit (GluRA) knockout                      Impaired                 Bannerman et al. ([@B8])
  Spatial     Brain and spinal cord myelin deficient                      Impaired                 Elias and Eleftheriou ([@B43])
  Spatial     APP/PS1 transgenic                                          Age-related impairment   Filali and Lalonde ([@B47])
  Spatial     Ts65Dn cholinergic deficient Down\'s model                  Impaired                 Granholm et al. ([@B58])
  Spatial     DARPP-32 knockout                                           Impaired                 Heyser et al. ([@B63])
  Spatial     PEPCK bGH transgenic elevated growth hormone                Facilitated              Meliska et al. ([@B89])
  Spatial     APP/PS1 transgenic Alzheimer\'s model                       None                     O\'Leary and Brown ([@B92])
  Spatial     AMPA receptor subunit (GluRA) knockout                      Impaired                 Schmitt et al. ([@B104])

*IDS/EDS, intra-dimensional/extra-dimensional shifting task; MWM, Morris water maze*.

Concluding Remarks
==================

The Brigman et al. data raise some interesting questions for further studies examining the effects of subchronic PCP on reversal in the touchscreen system. For example, would increasing the difficulty of the reversal (e.g., by increasing the perceptual similarity of the visual stimuli), presenting distracters, or making reinforcement probabilistic, increase the sensitivity of the assay to PCP treatment? Such task-dependent effects would be intriguing, given the aforementioned clinical data hinting that the range of executive deficits may increase in tandem with disease chronicity and severity. In this context, another interesting course would be to parametrically vary dose and/or chronicity of treatment to ask whether more "intensive" treatment regimens produced significant reversal deficits. Beyond the subchronic PCP model, the touchscreen-based system has great potential for evaluating mouse models of schizophrenia and, indeed, for other neuropsychiatric disorders characterized by cognitive inflexibility and other executive dysfunctions, such as depression (Holmes and Wellman, [@B64]) and drug addiction (Schoenbaum and Shaham, [@B107]). In concert with more established assays described above, the system could provide a valuable behavioral platform for elucidating the aberrant neural, molecular and genetic mechanisms underlying cognitive inflexibility in these disorders.
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Executive functions

:   A collection of higher-order mental processes that exert control over information processing, allowing for the ability to control, adapt and direct behavior in a manner appropriate to current environmental demands. These include, but are not limited to, attention, working memory, behavioral flexibility and inhibition, and decision making. These processes are mediated by a well-conserved neural circuitry, including the prefrontal cortex (PFC) and interconnected subcortical regions, such as the striatum.

Reversal learning

:   A measure of cognitive flexibility applicable across species in which subjects first learn a stimulus-reward association, then the reward association is switched. This ostensibly simple process taxes multiple executive functions, including attention, working memory and response inhibition.

Cognitive flexibility

:   Cognitive flexibility is a critical executive function that can be broadly defined as the ability to adapt behaviors in response to changes in the environment. The Wisconsin Card Sorting Task (WCST) is commonly used to test cognitive flexibility in schizophrenic patients, and analogs have been developed for rodents (e.g., Birrell and Brown "digging task," Birrell and Brown, [@B10]).

Touchscreen-based operant system

:   A system in which rats and mice learn to discriminate and reverse between two visual stimuli projected onto a touch-sensitive computer screen. It provides a procedure more analogous and comparable to reversal tasks employed in human subjects. Can be readily modified to test for a battery of cognitive and executive functions.

Subchronic PCP "model" of schizophrenia

:   Based on the clinical observation that phencyclidine (PCP) and other NMDAR antagonists mimic symptoms of schizophrenia in healthy individuals, Jentsch and Roth ([@B73]) developed a procedure involving repeated treatment of monkeys and rodents with PCP to produce cognitive deficits and associated prefrontal neurochemical abnormalities.
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